目的探讨在慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者体内联用左氧氟沙星(levofloxacin,LVFX)和多索茶碱(doxofylline,DFL)时,LVFX对DFL药动学的影响。方法采用RP-HPLC测定COPD患者单用DFL及与LVFX联用后DFL的血药浓度。用3P97软件进行药动学分析,比较两组DFL药动学参数的变化。结果DFL单用组及与LVFX合用组主要药动学参数Vc分别为(26.53±11.77)和(19.20±8.28)h;t_1/2α分别为(0.05±0.01)和(0.04±0.01)h;t_1/2β分别为(1.72±0.44)和(1.80±0.41)h;AUC分别为(31.06±6.29)和(35.28±7.02)mg·h·L^-1;CLs分别为(23.64±5.02)和(20.78±4.77)L·h^-1。两组各药动学参数差异均无显著性。结论LVFX对COPD患者DFL的药动学过程无影响,提示两者联合应用相对安全。

OBJECTIVE To study the effect of levofloxacin(LVFX) on pharmacokinetics of doxofylline(DFL) in chronic obstructive pulmonary disease patients.METHODS The serum concentration of DFL in COPD patients was determined by RP-HPLC after administrations of DFL and DFL+LVFX.The data of the serum concentration of DFL was analyzed by 3P97 software and the main pharmacokinetic parameters were compared beween the two groups.RESULTS The main pharmacokinetic parameters of the group treated with DFL alone and the group treated with DFL and LVFX were respectively Vc(26.53±11.77) and(19.20±8.28)h;t_1/2α(0.05±0.01) and(0.04±0.01)h;t_1/2β(1.72±0.44) and(1.80±0.41)h;AUC(31.06±6.29) and(35.28±7.02) mg·h·L^-1; CLs(23.64±5.02) and(20.78±4.77) L·h^-1.There was no significant difference between the main parameters of the two groups.CONCLUSION LVFX may not change remarkably the pharmacokinetics of DFL in COPD patients,which indicates that the concomitance of LVFX and DFL is relatively safe.